Evolent Health, Inc (NYSE:EVH) CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total value of $386,799.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Frank J. Williams also recently made the following trade(s):

  • On Thursday, July 6th, Frank J. Williams sold 16,300 shares of Evolent Health stock. The shares were sold at an average price of $24.76, for a total value of $403,588.00.
  • On Friday, May 19th, Frank J. Williams sold 114,865 shares of Evolent Health stock. The stock was sold at an average price of $24.30, for a total value of $2,791,219.50.

Shares of Evolent Health, Inc (NYSE EVH) opened at 24.10 on Monday. The stock’s market cap is $1.39 billion. Evolent Health, Inc has a 1-year low of $14.50 and a 1-year high of $27.50. The company’s 50-day moving average price is $25.82 and its 200 day moving average price is $22.62.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $104.38 million. During the same quarter last year, the business posted ($0.16) EPS. Evolent Health’s quarterly revenue was up 116.2% compared to the same quarter last year. Equities analysts forecast that Evolent Health, Inc will post ($0.41) EPS for the current fiscal year.

WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/evolent-health-inc-nyseevh-ceo-sells-386799-00-in-stock.html.

Several large investors have recently bought and sold shares of EVH. Swiss National Bank raised its stake in Evolent Health by 51.7% in the first quarter. Swiss National Bank now owns 61,000 shares of the technology company’s stock worth $1,360,000 after buying an additional 20,800 shares during the period. Highbridge Capital Management LLC acquired a new stake in shares of Evolent Health during the fourth quarter worth $1,390,000. Fox Run Management L.L.C. acquired a new stake in shares of Evolent Health during the second quarter worth $363,000. US Bancorp DE raised its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after buying an additional 19 shares during the period. Finally, PEAK6 Investments L.P. acquired a new stake in shares of Evolent Health during the first quarter worth $342,000. Institutional investors and hedge funds own 73.16% of the company’s stock.

A number of equities analysts have recently commented on the company. BidaskClub downgraded Evolent Health from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Robert W. Baird reissued an “outperform” rating and set a $35.00 price objective (up from $30.00) on shares of Evolent Health in a research report on Wednesday, June 14th. TheStreet raised Evolent Health from a “d” rating to a “c-” rating in a research report on Monday, May 22nd. Jefferies Group LLC reissued a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a research report on Thursday, April 13th. Finally, Leerink Swann reissued an “outperform” rating and set a $32.00 price objective (up from $30.00) on shares of Evolent Health in a research report on Monday, June 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $30.10.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.